Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. Show more
Location: 60 First Street, Cambridge, MA, 02141, United States | Website: https://primemedicine.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
595.4M
52 Wk Range
$1.11 - $5.17
Previous Close
$3.34
Open
$3.40
Volume
1,257,666
Day Range
$3.25 - $3.46
Enterprise Value
613.4M
Cash
101.8M
Avg Qtr Burn
-24.98M
Insider Ownership
18.19%
Institutional Own.
44.28%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PM359 Details Chronic granulomatous disease | Phase 1/2 Update |